EN DE
STOCK COMPARISON

Jd Health International Inc vs Raia Drogasil SA: Fair Value & Quality

Both stocks run through our valuation models. Here is how Jd Health International Inc (6618) and Raia Drogasil SA (RADLY) compare, as of Aug 11, 2026.

As of Aug 11, 2026, Fair Value Calculator sees Jd Health International Inc as the less overvalued of the two: Jd Health International Inc trades at HK$40.08 versus a fair value of HK$33.28 (-17%), while Raia Drogasil SA trades at $3.90 versus $2.42 (-38%).
Jd Health International Inc
6618.HK · HKD · Health Care
-17%
upside to fair value
overvalued
PriceHK$40.08
Fair ValueHK$33.28
Quality72/100
Raia Drogasil SA
RADLY · USD · Consumer Staples
-38%
upside to fair value
overvalued
Price$3.90
Fair Value$2.42
Quality53/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Jd Health International IncRaia Drogasil SA
Valuation
17.6×P/E (TTM)22.2×
1.48×P/S (TTM)0.13×
1.81×P/B0.80×
19.4×EV/EBITDA2.5×
1.26×PEG
Dividend yield2.3%
Dividend per share$0.32
Profitability
7%Net margin3%
4%Operating margin4%
9%Return on equity19%
3%Return on assets7%
Growth
28%Revenue growth (YoY)14%
16.3%Avg. growth/yr (3Y)14.3%
30.5%Avg. growth/yr (5Y)16.7%
Balance & size
Debt / equity0.46×
$14BMarket cap$6B
healthyGrowth qualityhealthy

Jd Health International Inc leads: 6 to 5 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Jd Health International Incof which business quality 74 · market factors 22 Raia Drogasil SAof which business quality 53 · market factors 54
ProfitabilityMargins and returns on capital today
47
61
Quality GrowthAre margins and returns improving?
80
40
CashflowEarnings quality: real cash, not paper profit
76
40
Fin. StrengthBalance sheet, leverage, solvency risk
100
42
InvestmentDisciplined investing over empire-building
66
56
Low VolatilityCalm price path (market factor)
42
55
MomentumPrice trend over the last 3–12 months (market factor)
12
43
52W MomentumDistance to the 52-week high (market factor)
18
74
Net IssuanceBuybacks instead of dilution
73
87

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Jd Health International Inc

DCF ModelsHK$70.32
Earnings-BasedHK$51.28
MultiplesHK$28.65
Asset-BasedHK$12.62
Growth DCFHK$77.68
Economic ProfitHK$20.89
Growth EarningsHK$70.00

10 of 24 models see the stock below the current price.

Raia Drogasil SA

DCF Models$23.09
Earnings-Based$14.97
Dividend Discount$5.97
Multiples$16.43
Asset-Based$2.80
Growth DCF$19.25
Economic Profit$12.91
Growth Earnings$20.30

1 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Jd Health International Inc
Bear HK$25.37Fair Value HK$33.28Bull HK$41.60
HK$40.08 = current price (white tick)
Raia Drogasil SA
Bear $1.81Fair Value $2.42Bull $3.92
$3.90 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Jd Health International Inc · Health Care

Quality score72 · Top 25%
Fair value upside-17% · above median

Raia Drogasil SA · Consumer Staples

Quality score53 · below median
Fair value upside-38% · below median

Bottom line

As of Aug 11, 2026, Fair Value Calculator sees Jd Health International Inc as the less overvalued of the two: Jd Health International Inc trades at HK$40.08 versus a fair value of HK$33.28 (-17%), while Raia Drogasil SA trades at $3.90 versus $2.42 (-38%).

Jd Health International Inc has the higher quality score (72/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.